Remodulin Injection, Solution
Product Images NDC 66302-101

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Remodulin (NDC 66302-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by United Therapeutics Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Remodulin 01)

FDA Label Image

Figure 1 (Remodulin 02)

FDA Label Image

Principal Display Panel (1 mg/mL Vial Carton)

FDA Label Image

Principal Display Panel (2.5 mg/mL Vial Carton)

This text contains information about a medication called REMODULIN (treprostinil) Injection that comes in a 20 mL multidose vial. The medication is intended for subcutaneous or intravenous infusion only and must be diluted prior to intravenous infusion. Each mL of the medication contains 2.5 mg treprostinil, along with other ingredients such as sodium citrate, sodium chloride, and metacresol. The package insert provides information about dosage and administration. The medication is manufactured by United Therapeutics Corp. in RTP, NC, USA. Storage instructions indicate that the medication should be kept at 25°C with excursions permitted to 2:30°C.*

FDA Label Image

Principal Display Panel (5 mg/mL Vial Carton)

REMODULIN is a medication given through subcutaneous or intravenous infusion for the treatment of pulmonary arterial hypertension. It is available in a 20 ml multidose vial containing 100 mg/20 mL of treprostinil injection with added Hydrochloric acid and Sodium hydrard to adjust pH level. The medication is being manufactured by United Therapeutics Corp. Note: technology has inaccurately recognized certain words/characters in the original text, and as a result, some of the information may not be entirely accurate.*

FDA Label Image

Principal Display Panel (10 mg/mL Vial Carton)

FDA Label Image

Principal Display Panel (50mL Vial Carton)

Remodulin is a medication that is administered either through subcutaneous or intravenous infusion. This medication contains treprostinil, which must be diluted before use. Remodulin comes in a 20 mL multidose vial containing 400 mg/20 mL (20 mg/mL) of the medication. The dosage and administration instructions are available in the package insert. The medication must be kept out of reach of children. The text also includes information about the composition of the medication and the storage conditions.*

FDA Label Image

Remodulin 08

This text provides information on a sterile diluent that is meant to be used only for intravenous infusion with REMODULIN (treprostinil) injection. The diluent contains alycine, sodium chloride, sodium hydroxide, and water for injection. It also provides storage instructions and a product code.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.